Sunday , October 22 2017
Home / Therapies / GLP-1 Agonist Therapy Center (page 12)

GLP-1 Agonist Therapy Center

GLP-1 Diabetes Drug Treatment: GLP-1 (glucagon-like peptide 1 receptor agonists) are incretin mimetics which have several benefits for diabetes management. They suppress post-prandial glucagon release, delay stomach emptying, and increase insulin sensitivity. Significantly lower rates of hypoglycemia accompany GLP-1 therapy. This class also has the side effect of modest weight reduction and reduction of systolic blood pressure. GLP-1 receptor agonists are counter-indicated for patients with a history of pancreatitis.

Oxyntomodulin: Partner to GLP-1?

Oxyntomodulin is a gut peptide released in response to a meal. It is synthesized within specialized enteroendocrine cells called L cells. Oxyntomodulin is released from the intestinal L cells 5-10 minutes after ingestion of food in amounts proportional to calorie intake and levels peak 30 minutes after meals. Oxyntomodulins are ...

Read More »

GLP-1 Knowledge Survey Part IV

GLP-1-6-Ch1

When making a choice amongst GLP-1 Agonists, the number of injections per day and when peak concentrations are reached are both important in selecting therapy. There was almost unanimous consensus that Exenatide is administered twice daily while Liraglutide is given only one time a day. It was interesting to note ...

Read More »